SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

TactiCath

Contact Force Ablation Catheter, Sensor Enabled

TactiCath
Clinical Evidence

Clinical Evidence

TactiSense IDE: TactiCath Catheter, Sensor Enabled Safety and Effectiveness

Study Conclusion: The TactiSense IDE results through 30 days demonstrate that the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ is safe and effective for the treatment of paroxysmal atrial fibrillation.
(TactiSense IDE study. TactiCath SE IFU #ARTEN600049107 A, 2018-09.)

TactiSense IDE study – included in TactiCath SE catheter IFU

  • Prospective, multi‐center, single‐arm clinical trial to demonstrate acute safety and effectiveness of TCSE for treatment of PAF
  • Study met primary endpoints
    • Safety: Rate of device or procedure-related primary SAEs within 7 days
    • Effectiveness: Acute procedural success, defined as confirmation of entrance block in all pulmonary veins

Endpoints

  • There are two primary endpoints and ten descriptive endpoints. Results of the primary endpoints and first three descriptive endpoints were analyzed for this primary analysis. The remaining endpoints will be reported after 1-year follow up results are available.
  • Primary Safety: The rate of primary device or procedure-related serious adverse events (SAEs) occurring within 7 days of the index procedure. Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur >7 days post procedure through 30 days also contributed to the primary endpoint. Primary event criteria were prespecified.
  • Primary Effectiveness: Acute procedural success, defined as confirmation of entrance block in all pulmonary veins.
  • Descriptive endpoints:
    1. Ablation data collected during the procedure, including: Power, Temperature, Irrigation flow rate, Contact Force, Procedure time, Total ablation time, Total fluoroscopy time, Total RF application time, Use of AutoMark
    2. Proportion of index cases achieving ≥90% lesions with ≥10 g contact force
    3. SAEs and adverse events related to the procedure and/or ablation catheter through 30 days

TactiSense met primary safety endpoint

The observed rate of primary safety endpoint events was 4.7% (one-sided 95% upper confidence limit: 8.64%) and was statistically significantly lower than the predetermined performance goal of 16.2% (p<0.0001) for the TactiCath Contact Force Ablation Catheter, Sensor Enabled.

Chart showing the primary safety endpoint of 4.7% and performance goal of 16.2% for the TactiCath Ablation Catheter, SE.
Primary Safety Endpoint (SAF population)Tacticath SE (N=149)Upper One-sided 95% CLPerformace Goal1P-value2
Subject experienced primary safety endpoint event (Device or procedure-related primary SAE)7 (4.7%)(8.64%)16.2%<0.0001

 

1One-sided upper 95% confidence limit by Clopper Pearson Method.
2One-sided p-value by using Binomial Exact Test against the performance goal of 16.2%, to be compared with one-sided significance level of 0.05.

TactiSense primary safety endpoint events

TactiSense IDE Primary Safety Endpoint Events (SAF population)N (%) Subjects, N=149
Atrial-esophageal fistula1 (0.7%)
AV block0 (0.0%)
Cardiac perforation/tamponade3 (2.0%)
Death0 (0.0%)
Diaphragmatic paralysis0 (0.0%)
Gastroparesis0 (0.0%)
Hospitalization0 (0.0%)
Myocardial Infarction0 (0.0%)
Pericarditis1 (0.7%)
Pneumothorax0 (0.0%)
Pulmonary edema0 (0.0%)
Pulmonary vein stenosis0 (0.0%)
Stroke0 (0.0%)
Thromboembolism1 (0.7%)
Transient ischemic attack0 (0.0%)
Vascular Access Complication2 (1.3%)
Total Device or Procedure-related Primary SAEs0 (0.0%)

TactiSense met primary effectiveness endpoint

Acute procedural success was achieved in 98.0% (148/151) subjects who had the TactiCath Contact Force Ablation Catheter, Sensor Enabled inserted into the vasculature. The lower bound of the one-sided 95% confidence interval was 94.95%, which is greater than the performance goal of 90%. Therefore, the null hypothesis was rejected and the primary effectiveness endpoint passed.

Chart showing 94.95 lower confidence limit and 98% acute procedural success achievement of the TactiCath Ablation Catheter, SE.
Primary Effectiveness Endpoint (EFF population)Tacticath SE (N=151)Lower One-sided 95% CL1Performace GoalP-value2
Acute Procedure Success*98.0 (148/151)94.95%90%0.0001

 

1One-sided lower 95% confidence limit by Clopper Pearson Method.
2One-sided p-value by using Binomial Exact Test against the performance goal of 90%, to be compared with one-sided significance level of 0.05.
*The primary effectiveness endpoint was acute procedure success, defined as confirmation of entrance block at least 30 minutes after the last ablation in each pulmonary vein.

 

TactiSense IDE: Key procedural results

TactiSense IDE Descriptive Endpoints Procedural Characteristics(EFF Population) Total N=150
Was the recommended power of 10-30W used? (% Yes)58.7% (88/150)
Average RF power (W)Median (Q1, Q3): 29.0 (26.0, 32.0) (n=149)
Average contact force (g) per subjectMean ± SD: 12.1 ± 4.7
Median (Q1, Q3): 11.2 (8.5, 14.3)
Range (min, max): (5.0, 32.0)
(n = 149)
% of patients achieving ≥ 90% lesions with ≥10 g contact force3.4% (5/149)
Total procedure time (min)Median (Q1, Q3): 159.5 (123.0, 206.0) (n=150)
Total RF time (entire case in min)Median (Q1, Q3): 35.7 (28.9, 51.9) (n=149)
Fluoroscopy time (min)Median (Q1, Q3): 9.0 (5.0, 16.0) (n=150)
AutoMark turned on for procedure? (Yes)99.3% (149/150)
Was AutoMark used to guide therapy? (Yes)92.6% (125/135)

 

1 TactiSense IDE study. TactiCath SE IFU #ARTEN600049107 A, 2018-09.

 

Additional clinical study information:

  • TactiCath Contact Force Ablation Catheter, Sensor Enabled Clinical Study Summary

    This summary describes two clinical studies: The TOCCASTAR clinical study is conducted for the TactiCath™ Set, which also supports the TactiCath™ Quartz Set. The TactiSense study is conducted to demonstrate the acute safety and effectiveness of ablation with the TactiCath Contact Force Ablation Catheter, Sensor Enabled, for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.

 

*Effortless handling is based on how physicians scored catheter handling characteristics during an initial market release.

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service

MAT-2103109 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0